ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

LPSN INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that LivePerson, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of LivePerson, Inc. (NASDAQ: LPSN) publicly traded securities between May 10, 2022 and March 16, 2023, both dates inclusive (the “Class Period”) have until June 23, 2023 to seek appointment as lead plaintiff of the LivePerson class action lawsuit. Captioned Straub v. LivePerson, Inc., No. 23-cv-03078 (E.D.N.Y.), the LivePerson class action lawsuit charges LivePerson as well as certain of its top executives with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the LivePerson class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-liveperson-inc-class-action-lawsuit-lpsn.html

You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at jsanchez@rgrdlaw.com.

CASE ALLEGATIONS: LivePerson delivers mobile and online messaging solutions through Conversation Artificial Intelligence. In 2022, LivePerson completed its acquisition of WildHealth, Inc. which purports to “analyze [patients’] DNA, biometrics, and lifestyle activity to provide a blueprint for maximizing [patients’] health span.”

The LivePerson class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) LivePerson failed to address any material weaknesses with internal controls; (ii) LivePerson’s third quarter financial statements, ended in September 30, 2022, failed to disclosed WildHealth’s suspension of Medicare reimbursement; and (iii) as a result, LivePerson’s fourth quarter 2022 revenue would be affected.

On February 28, 2023, LivePerson announced that it would be unable to timely file its annual report. LivePerson further revealed that Medicare reimbursement was suspended with respect to a recently discontinued WildHealth program. On this news, the price of LivePerson stock declined more than 14%.

Then, on March 6, 2023, LivePerson announced that a “review of WildHealth revenue is anticipated to affect fourth quarter 2022 revenue attributable to WildHealth’s participation in a Medicare demonstration program, due to suspension in November 2022 of Medicare reimbursements under the program and pending further governmental review.” On this news, the price of LivePerson stock declined further.

Finally, on March 16, 2023, LivePerson reported that “due to certain control deficiencies which aggregated to a material weakness in [LivePerson’s] internal control over financial reporting . . . [LivePerson’s] disclosure controls and procedures were not effective as of December 31, 2022.” On this news, the price of LivePerson stock decline more than 57%, further damaging investors.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired LivePerson publicly traded securities during the Class Period to seek appointment as lead plaintiff of the LivePerson class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the LivePerson class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the LivePerson class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the LivePerson class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller is one of the world’s leading complex class action firms representing plaintiffs in securities fraud cases. The Firm is ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report for recovering more than $1.75 billion for investors in 2022 – the third year in a row Robbins Geller tops the list. And in those three years alone, Robbins Geller recovered nearly $5.3 billion for investors, more than double the amount recovered by any other plaintiffs’ firm. With 200 lawyers in 9 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Attorney advertising.

Past results do not guarantee future outcomes.

Services may be performed by attorneys in any of our offices.

Contacts

Robbins Geller Rudman & Dowd LLP

655 W. Broadway, Suite 1900, San Diego, CA 92101

J.C. Sanchez, 800-449-4900

jsanchez@rgrdlaw.com

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.